Modern aspects of pathogenesis of comorbidity of non-alcoholic fatty liver disease and hypertension in the presence or absence of chronic kidney disease.
-
Published:2022
Issue:1
Volume:2022
Page:55-63
-
ISSN:2411-1457
-
Container-title:Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini
-
language:
-
Short-container-title:Shidnoevr. z. vnutr. simejnoi med.
Author:
Prosolenko K.O., ,Lapshyna К.A.,Ryabuha V.V., ,
Abstract
The article presents the main aspects of the pathogenesis of comorbidity of non-alcoholic fatty liver disease and hypertension. These diseases are very often presented as comorbidities in a large number of patients and can independently impair renal function. According to the literature and the results of our own research, the role of insulin resistance, disorders of lipid and carbohydrate metabolism, cytokine imbalance, disorders of the antioxidant defense system in the pathogenesis of this comorbidity was analyzed. The effect of hypoadictinemia and increased blood levels of fetuin-A and cytokeratin-18 on this comorbidity was also assessed. The independent effect of non-alcoholic fatty liver disease on renal function, arterial stiffness and the occurrence of diastolic heart function was analyzed. The interaction between non-alcoholic fatty liver disease and hypertension depending on the presence of chronic kidney disease was also evaluated. Key words: nonalcoholic fatty liver disease, hypertension, pathogenesis, comorbidity, renal impairment.
Publisher
National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications)
Reference85 articles.
1. 1. Estes C, Anstee Q, Arias-Loste M, Bantel H, Bellentani S, Caballeria J, Colombo M, Craxi A, Crespo J, Day C, Eguchi Y, Geier A, Kondili L, Kroy D, Lazarus J, Loomba R, Manns M, Marchesini G, Nakajima A, Negro F, Petta S, Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg J, Tacke F, Tanaka J, Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of Hepatology. 2018;69(4):896-904. http://dx.doi.org/10.1016/j.jhep.2018.05.036 2. 2. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation. Transplantation. 2019;103(1):22-7. doi: 10.1097/TP.0000000000002484. 3. 3. Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with metaanalysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther. 2018;48(7):696-703. doi: 10.1111/apt.14937 4. 4. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement D, Coca A, De Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen S, Kreutz R, Laurent S, Lip G, McManus R, Narkiewicz K, Ruschitzka F, Schmieder R, Shlyakhto E, Tsioufis K, Aboyans V, Desormais I. 2018 Practice Guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. Journal of Hypertension. 2018;36(12):2284-2309. http://dx.doi.org/10.1097/hjh.0000000000001961 5. Perazzo H, Poynard T, Dufour JF The interactions of nonalcoholic fatty liver disease and cardiovascular diseases;5;Clin Liver Dis,2014
|
|